表紙
市場調查報告書

介入性腫瘤學的全球市場預測 2024年:高頻,微波,冷凍切除,栓塞術,導管導引線

Interventional Oncology Market by Product (Radiofrequency, microwave, cryoablation, embolization, guidewires), Procedures (Thermal Ablation, Non-Thermal Ablation, TACE, TARE, TAE), Cancer (Liver, Lung, Kidney, Bone Metastasis) - Global Forecast to 2024

出版商 MarketsandMarkets 商品編碼 810802
出版日期 內容資訊 英文 181 Pages
訂單完成後即時交付
價格
Back to Top
介入性腫瘤學的全球市場預測 2024年:高頻,微波,冷凍切除,栓塞術,導管導引線 Interventional Oncology Market by Product (Radiofrequency, microwave, cryoablation, embolization, guidewires), Procedures (Thermal Ablation, Non-Thermal Ablation, TACE, TARE, TAE), Cancer (Liver, Lung, Kidney, Bone Metastasis) - Global Forecast to 2024
出版日期: 2019年03月13日內容資訊: 英文 181 Pages
簡介

全球介入性腫瘤學市場規模,預測將從2019年的20億美元到2024年達到29億美元,在預測期間中預計將以6.8%的年複合成長率 (CAGR) 擴大。該市場的成長,主要由於對微創手術的偏好高漲,標的患者人口的擴大,癌症研究的公民營資金、政府支援的增加,介入性腫瘤學領域的技術進步,及介入性腫瘤學、癌症研究相關的政府投資、資金的增加而受到促進。可是,熟練的放射線科醫生、癌症專門醫生的不足,介入性腫瘤學治療的高成本性,及不利的法規等,某種程度抑制著該市場的成長。

本報告提供全球介入性腫瘤學市場現況與展望調查分析,市場概要,各產品、治療、癌症種類、區域區隔的收益成果、預測,產業趨勢,及主要企業簡介等資訊。

第1章 簡介

第2章 調查手法

第3章 摘要整理

第4章 重要考察

  • 介入性腫瘤學:市場概要
  • 介入性腫瘤學市場地區分析:各產品
  • 亞太地區的介入性腫瘤學市場:各類型
  • 歐洲的介入性腫瘤學市場:各癌症類型
  • 介入性腫瘤學市場:各治療
  • 介入性腫瘤學市場地區概要

第5章 市場概要

  • 簡介
  • 市場動態
    • 市場成長的推動要素
    • 市場成長的阻礙要素
    • 市場機會
    • 市場課題
  • 市場趨勢

第6章 介入性腫瘤學市場:各產品

  • 簡介
  • 栓塞設備
  • 切除設備
  • 支援設備

第7章 介入性腫瘤學市場:各治療

  • 簡介
  • 熱腫瘤切除
  • 非熱腫瘤切除
  • 肝動脈化學栓塞療法 (TACE)
  • 肝動脈放射線栓塞療法(TARE)/選擇性體內放射療法 (SIRT)
  • 肝動脈栓塞療法 (TAE) /BLAND栓塞

第8章 介入性腫瘤學市場:各癌症類型

  • 簡介
    • 肝癌
    • 肺癌
    • 骨癌
    • 腎臟癌
    • 其他癌症

第9章 介入性腫瘤學市場:各地區

  • 簡介
  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 中東、非洲

第10章 競爭環境

  • 概要
  • 全球市場佔有率分析
  • 競爭情形
  • VENDOR DIVE的概要
  • VENDOR INCLUSION CRITERIA
  • VENDOR DIVE

第11章 企業簡介

  • HEALTHTRONICS, INC. 142
  • TROD MEDICAL 144
  • SANARUS TECHNOLOGIES, INC. 145
  • TELEFLEX, INC. 146
  • IMBIOTECHNOLOGIES LTD. 148
  • MEDWAVES, INC. 149
  • ICECURE MEDICAL 150
  • TERUMO CORPORATION 151
  • MEDTRONIC PLC 154
  • BTG PLC 158
  • JOHNSON & JOHNSON 161
  • MERIT MEDICAL SYSTEMS, INC. 163
  • BOSTON SCIENTIFIC CORPORATION 166
  • ANGIODYNAMICS, INC. 169
  • COOK MEDICAL

第12章 附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: MD 6975

"The global interventional oncology market is projected to grow at a CAGR of 6.8% during the forecast period"

Interventional oncology refers to the use of minimally invasive procedures performed for the diagnosis, treatment, or palliative care of cancer. The global interventional oncology market is projected to reach USD 2.9 billion by 2024 from USD 2.0 billion in 2019, at a CAGR of 6.8% from 2019 to 2024. The growth of this market is primarily driven by the rising preference for minimally invasive procedures, expansion of the target patient population, increasing public-private funding and government support for cancer research, technological advancements in the field of interventional oncology, and increasing government investments and funding for interventional oncology and related cancer research. However, the dearth of well-trained and skilled radiologists and oncologists, high costs of interventional oncology procedures, and unfavorable regulations are expected to limit market growth to a certain extent.

"The transcatheter arterial radioembolization TARE or selective internal radiation therapy SIRT segment accounted for the largest share of the global interventional oncology market during the forecast period"

On the basis of procedure, the interventional oncology market is segmented into thermal tumor ablation, non-thermal tumor ablation, transcatheter arterial chemoembolization TACE, transcatheter arterial radioembolization TARE or selective internal radiation therapy SIRT, and transcatheter arterial embolization TAE or bland embolization procedures. In 2018, the TARE/SIRT procedures segment accounted for the largest share of this market majorly due to the rising prevalence of cancer, increasing demand for minimally invasive procedures, growing adoption of embolization procedures, and the clinical efficacy of Yttrium-90 radioembolic agents which are used in these procedures.

"The liver cancer segment accounted for the largest share of the interventional oncology market during the forecast period"

Based on cancer type, the interventional oncology market is segmented into liver cancer, lung cancer, kidney cancer, bone cancer, and other cancers. The other cancers segment includes pediatric cancer, prostate cancer, and breast cancer. The liver cancer segment accounted for the largest share in the interventional oncology market in 2018.

"Europe accounted for the second-largest share of the global market in 2018"

The interventional oncology market is segmented into five major regions, namely North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Europe accounted for the second-largest share in 2018. The rising incidence of cancer, coupled with the growing geriatric population in Europe, is a key factor propelling the demand for interventional oncology products in this region. Prominent market players are focusing on improving the quality of patient care across Europe by commercializing advanced products, investing in technological innovations, and partnering with other institutions and organizations for spreading cancer awareness. This is another major factor driving market growth.

Breakdown of supply-side primary interviews:

  • By Company Type: Tier 1 - 25%, Tier 2 - 30%, and Tier 3 - 45%
  • By Designation: C-level - 26%, Director-level - 30%, and Others - 44%
  • By Region: North America - 34%, Europe - 26%, APAC - 23%, and RoW - 17%

The major players in the market include Medtronic Ireland, Boston Scientific US, BTG plc UK, Merit Medical Systems US, and Terumo Japan. The other prominent players operating in the overall interventional oncology market include AngioDynamics US, Ethicon a part of J&J US, Teleflex US, Cook Medical US, HealthTronics US, MedWaves Medical US, Sanarus US, IMBiotechnologies Canada, Trod Medical US, IceCure Medical Israel, Mermaid Medicals Denmark, and Interface Biomaterials BV Netherlands, among others.

Research Coverage

This report studies the interventional oncology market based on products, procedure, cancer type, and region. The report also studies factors such as drivers, restraints, opportunities, and challenges affecting market growth. It also provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to four main regions and the respective countries in these regions.

Key Benefits of Buying the Report

This report focuses on various levels of analysis-industry trends, market shares of top players, and company profiles, which together form basic views. It also analyzes the competitive landscape; emerging segments of the interventional oncology market; and high-growth regions and their drivers, restraints, challenges, and opportunities. The report will help both established firms as well as new entrants/smaller firms to gauge the pulse of the market and garner greater market shares.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION
  • 1.3 MARKET SCOPE
    • 1.3.1 MARKETS COVERED
    • 1.3.2 YEARS CONSIDERED FOR THE STUDY
  • 1.4 CURRENCY
  • 1.5 STAKEHOLDERS

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • 2.1.1 SECONDARY DATA
      • 2.1.1.1 Key data from secondary sources
    • 2.1.2 PRIMARY DATA
      • 2.1.2.1 Key data from primary sources
  • 2.2 MARKET SIZE ESTIMATION
    • 2.2.1 PRODUCT-BASED MARKET ESTIMATION
    • 2.2.2 PRIMARY RESEARCH VALIDATION
  • 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
  • 2.4 RESEARCH LIMITATIONS AND ASSUMPTIONS
    • 2.4.1 LIMITATIONS
    • 2.4.2 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

  • 4.1 INTERVENTIONAL ONCOLOGY: MARKET OVERVIEW
  • 4.2 GEOGRAPHIC ANALYSIS: INTERVENTIONAL ONCOLOGY MARKET, BY PRODUCT
  • 4.3 ASIA PACIFIC: ABLATION DEVICES MARKET, BY TYPE (2018)
  • 4.4 EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE (2018)
  • 4.5 INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE,

2019 VS. 2024 (USD MILLION)

  • 4.6 GEOGRAPHICAL SNAPSHOT OF THE INTERVENTIONAL ONCOLOGY MARKET

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • 5.2.1 DRIVERS
      • 5.2.1.1 Rising patient preference for minimally invasive procedures
      • 5.2.1.2 Expansion of the target patient population
      • 5.2.1.3 Increasing public-private funding and government support for interventional oncology
      • 5.2.1.4 Technological advancements in interventional oncology
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Dearth of well-trained and skilled radiologists and oncologists
      • 5.2.2.2 Unfavorable regulations
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Emerging economies offer high growth potential
      • 5.2.3.2 Rising awareness about the benefits of interventional oncology
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Limited clinical data to support therapeutic efficacy
      • 5.2.4.2 Strong market positioning of alternative therapies
  • 5.3 MARKET TRENDS
    • 5.3.1 PERSONALIZED OR PRECISION INTERVENTIONAL ONCOLOGY

6 INTERVENTIONAL ONCOLOGY MARKET, BY PRODUCT

  • 6.1 INTRODUCTION
  • 6.2 EMBOLIZATION DEVICES
    • 6.2.1 INTERVENTIONAL ONCOLOGY EMBOLIZATION DEVICES MARKET SPLIT,

BY PROCEDURE 51

    • 6.2.2 INTERVENTIONAL ONCOLOGY EMBOLIZATION DEVICES MARKET SPLIT,

BY CANCER TYPE 52

    • 6.2.3 RADIOEMBOLIC AGENTS
      • 6.2.3.1 Radioembolic agents dominated the interventional oncology embolization devices market in 2018
        • 6.2.3.1.1 Radioembolic agents market split, by procedure
        • 6.2.3.1.2 Radioembolic agents market split, by cancer type
    • 6.2.4 NON-RADIOACTIVE EMBOLIC AGENTS
      • 6.2.4.1 Embolization procedures cannot be used to treat cancers in advanced stages, which is a major factor restraining market growth
        • 6.2.4.1.1 Non-radioactive embolic agents market split, by procedure
        • 6.2.4.1.2 Non-radioactive embolic agents market split, by cancer type
  • 6.3 ABLATION DEVICES
    • 6.3.1 TECHNOLOGICAL ADVANCEMENTS IN ABLATION DEVICES- A KEY DRIVER FOR MARKET GROWTH
      • 6.3.1.1 Interventional oncology ablation devices market split, by procedure
      • 6.3.1.2 Interventional oncology ablation devices market split, by cancer type
    • 6.3.2 RADIOFREQUENCY (RF) ABLATION DEVICES
      • 6.3.2.1 Growing competition among different technologies offered by key players, backed by long-term clinical efficacy data, to drive the RF ablation devices market
        • 6.3.2.1.1 Radiofrequency ablation devices market split, by procedure
        • 6.3.2.1.2 Radiofrequency ablation devices market split, by cancer type
    • 6.3.3 MICROWAVE ABLATION DEVICES
      • 6.3.3.1 Microwave ablation enables the simultaneous treatment of multiple lesions-A key factor driving market growth
        • 6.3.3.1.1 Microwave ablation devices market split, by procedure
        • 6.3.3.1.2 Microwave ablation devices market split, by cancer type
    • 6.3.4 CRYOABLATION DEVICES
      • 6.3.4.1 Advantages of cryoablation over other thermal ablation techniques to drive market growth in the coming years
        • 6.3.4.1.1 Cryoablation devices market split, by procedure
        • 6.3.4.1.2 Cryoablation devices market split, by cancer type
    • 6.3.5 OTHER ABLATION DEVICES
        • 6.3.5.1.1 Other ablation devices market split, by procedure
        • 6.3.5.1.2 Other ablation devices market split, by cancer type
  • 6.4 SUPPORT DEVICES
    • 6.4.1 INTERVENTIONAL ONCOLOGY SUPPORT DEVICES MARKET SPLIT, BY PROCEDURE
    • 6.4.2 INTERVENTIONAL ONCOLOGY SUPPORT DEVICES MARKET SPLIT, BY CANCER TYPE
    • 6.4.3 MICROCATHETERS
      • 6.4.3.1 Regulatory approvals driving the growth of the microcatheters market
        • 6.4.3.1.1 Microcatheters market split, by procedure
        • 6.4.3.1.2 Microcatheters market split, by cancer type
    • 6.4.4 GUIDEWIRES
      • 6.4.4.1 Advancements in guidewire construction and the launch of new and advanced products are the major factors driving the growth of this market
        • 6.4.4.1.1 Guidewires market split, by procedure
        • 6.4.4.1.2 Guidewires market split, by cancer type

7 INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE

  • 7.1 INTRODUCTION
  • 7.2 THERMAL TUMOR ABLATION
    • 7.2.1 INCREASING CLINICAL EVIDENCE IS A MAJOR FACTOR DRIVING MARKET GROWTH
  • 7.3 NON-THERMAL TUMOR ABLATION
    • 7.3.1 NANOKNIFE HAS EMERGED AS A POTENTIAL ALTERNATIVE TO THERMAL TUMOR ABLATION TECHNIQUES

  • 7.4 TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION
    • 7.4.1 ABILITY TO TREAT SMALL AND LARGE-SIZED TUMORS - A MAJOR FACTOR DRIVING THE DEMAND FOR TACE PROCEDURES
  • 7.5 TRANSCATHETER ARTERIAL RADIOEMBOLIZATION/SELECTIVE INTERNAL

RADIATION THERAPY 79

    • 7.5.1 TARE SHOWS GREATER CLINICAL EFFICACY AS COMPARED TO TACE
  • 7.6 TRANSCATHETER ARTERIAL EMBOLIZATION/BLAND EMBOLIZATION
    • 7.6.1 INCREASING CLINICAL EVIDENCE FOR TARE AND TACE TO RESTRAIN GROWTH OF THIS MARKET

8 INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE

  • 8.1 INTRODUCTION
    • 8.1.1 LIVER CANCER
      • 8.1.1.1 Increasing disease prevalence and rising research activity are driving market growth
    • 8.1.2 LUNG CANCER
      • 8.1.2.1 Increasing number of cancer cases will drive the demand for interventional oncology procedures
    • 8.1.3 BONE CANCER
      • 8.1.3.1 Interventional oncology procedures can eliminate tumors directly and relieve pain
    • 8.1.4 KIDNEY CANCER
      • 8.1.4.1 Interventional oncology procedures are appropriate for patients with a genetic disposition for multiple tumors
    • 8.1.5 OTHER CANCERS

9 INTERVENTIONAL ONCOLOGY MARKET, BY REGION

  • 9.1 INTRODUCTION
  • 9.2 NORTH AMERICA
    • 9.2.1 US
      • 9.2.1.1 US to dominate the North American interventional oncology market
    • 9.2.2 CANADA
      • 9.2.2.1 Public-private initiatives to support the adoption of interventional oncology procedures in Canada
  • 9.3 EUROPE
    • 9.3.1 GERMANY
      • 9.3.1.1 Germany is the fastest-growing market in Europe
    • 9.3.2 UK
      • 9.3.2.1 Increasing awareness and support for cancer-related activities to drive market growth in the UK
    • 9.3.3 FRANCE
      • 9.3.3.1 Radiofrequency ablation dominated the ablation devices market in France
    • 9.3.4 REST OF EUROPE

  • 9.4 ASIA PACIFIC
    • 9.4.1 JAPAN
      • 9.4.1.1 Rising geriatric population and universal healthcare reimbursement are the major driving factors
    • 9.4.2 CHINA
      • 9.4.2.1 Increasing cancer incidence and growing patient population to drive market growth in China
    • 9.4.3 INDIA
      • 9.4.3.1 Improving research capabilities coupled with the expansion of key players to drive market growth in India
    • 9.4.4 REST OF ASIA PACIFIC
  • 9.5 LATIN AMERICA
    • 9.5.1 BRAZIL
      • 9.5.1.1 Brazil to account for the largest share of the Latin American interventional oncology market
    • 9.5.2 MEXICO
      • 9.5.2.1 Growing awareness campaigns and rising incidence of cancer to drive market growth in Mexico
    • 9.5.3 REST OF LATIN AMERICA
  • 9.6 MIDDLE EAST AND AFRICA
    • 9.6.1 IMPROVING HEALTHCARE INFRASTRUCTURE AND RISING INCIDENCE OF CANCER ARE DRIVING GROWTH IN THE MIDDLE EAST AND AFRICA

10 COMPETITIVE LANDSCAPE

  • 10.1 OVERVIEW
  • 10.2 GLOBAL MARKET SHARE ANALYSIS, 2018
  • 10.3 COMPETITIVE SCENARIO (2015 - 2019)
    • 10.3.1 KEY PRODUCT LAUNCHES
    • 10.3.2 KEY ACQUISITIONS
    • 10.3.3 KEY AGREEMENTS AND COLLABORATIONS
  • 10.4 VENDOR DIVE OVERVIEW
  • 10.5 VENDOR INCLUSION CRITERIA
  • 10.6 VENDOR DIVE
    • 10.6.1 VANGUARDS
    • 10.6.2 INNOVATORS
    • 10.6.3 DYNAMIC DIFFERENTIATORS
    • 10.6.4 EMERGING COMPANIES

11 COMPANY PROFILES

(Business Overview, Products Offered, Recent Developments, MnM View)*

  • 11.1 HEALTHTRONICS, INC.
  • 11.2 TROD MEDICAL
  • 11.3 SANARUS TECHNOLOGIES, INC.
  • 11.4 TELEFLEX, INC.
  • 11.5 IMBIOTECHNOLOGIES LTD.
  • 11.6 MEDWAVES, INC.
  • 11.7 ICECURE MEDICAL
  • 11.8 TERUMO CORPORATION
  • 11.9 MEDTRONIC PLC
  • 11.10 BTG PLC
  • 11.11 JOHNSON & JOHNSON
  • 11.12 MERIT MEDICAL SYSTEMS, INC.
  • 11.13 BOSTON SCIENTIFIC CORPORATION
  • 11.14 ANGIODYNAMICS, INC.
  • 11.15 COOK MEDICAL

Business Overview, Products Offered, Recent Developments, MnM View might not be captured in case of unlisted companies.

12 APPENDIX

  • 12.1 DISCUSSION GUIDE
  • 12.2 KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 12.3 AVAILABLE CUSTOMIZATIONS
  • 12.4 RELATED REPORTS
  • 12.5 AUTHOR DETAILS

LIST OF TABLES

  • TABLE 1 INTERVENTIONAL ONCOLOGY MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 2 RECENT PRODUCT LAUNCHES AND APPROVALS OF EMBOLIZATION DEVICES
  • TABLE 3 INTERVENTIONAL ONCOLOGY EMBOLIZATION DEVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 4 INTERVENTIONAL ONCOLOGY EMBOLIZATION DEVICES MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 5 INTERVENTIONAL ONCOLOGY EMBOLIZATION DEVICES MARKET, BY PROCEDURE, 2017-2024 (USD MILLION)
  • TABLE 6 INTERVENTIONAL ONCOLOGY EMBOLIZATION DEVICES MARKET, BY CANCER TYPE, 2017-2024 (USD MILLION)
  • TABLE 7 RADIOEMBOLIC AGENTS OFFERED BY MAJOR MARKET PLAYERS
  • TABLE 8 RADIOEMBOLIC AGENTS MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 9 RADIOEMBOLIC AGENTS MARKET, BY PROCEDURE, 2017-2024 (USD MILLION)
  • TABLE 10 RADIOEMBOLIC AGENTS MARKET, BY CANCER TYPE, 2017-2024 (USD MILLION)
  • TABLE 11 NON-RADIOACTIVE EMBOLIC AGENTS OFFERED BY MAJOR MARKET PLAYERS
  • TABLE 12 NON-RADIOACTIVE EMBOLIC AGENTS MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 13 NON-RADIOACTIVE EMBOLIC AGENTS MARKET, BY PROCEDURE, 2017-2024 (USD MILLION)
  • TABLE 14 NON-RADIOACTIVE EMBOLIC AGENTS MARKET, BY CANCER TYPE, 2017-2024 (USD MILLION)
  • TABLE 15 INTERVENTIONAL ONCOLOGY ABLATION DEVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 16 INTERVENTIONAL ONCOLOGY ABLATION DEVICES MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 17 INTERVENTIONAL ONCOLOGY ABLATION DEVICES MARKET, BY PROCEDURE, 2017-2024 (USD MILLION)
  • TABLE 18 INTERVENTIONAL ONCOLOGY ABLATION DEVICES MARKET, BY CANCER TYPE, 2017-2024 (USD MILLION)
  • TABLE 19 RADIOFREQUENCY ABLATION DEVICES OFFERED BY MAJOR MARKET PLAYERS
  • TABLE 20 RADIOFREQUENCY ABLATION DEVICES MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 21 RADIOFREQUENCY ABLATION DEVICES MARKET, BY PROCEDURE, 2017-2024 (USD MILLION)
  • TABLE 22 RADIOFREQUENCY ABLATION DEVICES MARKET, BY CANCER TYPE, 2017-2024 (USD MILLION)
  • TABLE 23 MICROWAVE ABLATION DEVICES MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 24 MICROWAVE ABLATION DEVICES MARKET, BY PROCEDURE, 2017-2024 (USD MILLION)
  • TABLE 25 MICROWAVE ABLATION DEVICES MARKET, BY CANCER TYPE, 2017-2024 (USD MILLION)
  • TABLE 26 CRYOABLATION DEVICES MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 27 CRYOABLATION DEVICES MARKET, BY PROCEDURE, 2017-2024 (USD MILLION)
  • TABLE 28 CRYOABLATION DEVICES MARKET, BY CANCER TYPE, 2017-2024 (USD MILLION)
  • TABLE 29 OTHER ABLATION DEVICES MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 30 OTHER ABLATION DEVICES MARKET, BY PROCEDURE, 2017-2024 (USD MILLION)
  • TABLE 31 OTHER ABLATION DEVICES MARKET, BY CANCER TYPE, 2017-2024 (USD MILLION)
  • TABLE 32 INTERVENTIONAL ONCOLOGY SUPPORT DEVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 33 INTERVENTIONAL ONCOLOGY SUPPORT DEVICES MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 34 INTERVENTIONAL ONCOLOGY SUPPORT DEVICES MARKET, BY PROCEDURE, 2017-2024 (USD MILLION)
  • TABLE 35 INTERVENTIONAL ONCOLOGY SUPPORT DEVICES MARKET, BY CANCER TYPE, 2017-2024 (USD MILLION)
  • TABLE 36 MICROCATHETERS MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 37 MICROCATHETERS MARKET, BY PROCEDURE, 2017-2024 (USD MILLION)
  • TABLE 38 MICROCATHETERS MARKET, BY CANCER TYPE, 2017-2024 (USD MILLION)
  • TABLE 39 GUIDEWIRES MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 40 GUIDEWIRES MARKET, BY PROCEDURE, 2017-2024 (USD MILLION)
  • TABLE 41 GUIDEWIRES MARKET, BY CANCER TYPE, 2017-2024 (USD MILLION)
  • TABLE 42 INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2017-2024 (USD MILLION)
  • TABLE 43 THERMAL TUMOR ABLATION PROCEDURES MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 44 NON-THERMAL TUMOR ABLATION PROCEDURES MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 45 TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION PROCEDURES MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 46 TRANSCATHETER ARTERIAL RADIOEMBOLIZATION/SELECTIVE INTERNAL RADIATION THERAPY PROCEDURES MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 47 TRANSCATHETER ARTERIAL EMBOLIZATION/BLAND EMBOLIZATION PROCEDURES MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 48 INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2017-2024 (USD MILLION)
  • TABLE 49 INTERVENTIONAL ONCOLOGY MARKET FOR LIVER CANCER, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 50 INTERVENTIONAL ONCOLOGY MARKET FOR LUNG CANCER, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 51 INTERVENTIONAL ONCOLOGY MARKET FOR BONE CANCER, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 52 INTERVENTIONAL ONCOLOGY MARKET FOR KIDNEY CANCER, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 53 INTERVENTIONAL ONCOLOGY MARKET FOR OTHER CANCERS, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 54 INTERVENTIONAL ONCOLOGY MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 55 NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 56 NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 57 NORTH AMERICA: INTERVENTIONAL ONCOLOGY ABLATION DEVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 58 NORTH AMERICA: INTERVENTIONAL ONCOLOGY EMBOLIZATION DEVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 59 NORTH AMERICA: INTERVENTIONAL ONCOLOGY SUPPORT DEVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 60 NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2017-2024 (USD MILLION)
  • TABLE 61 NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2017-2024 (USD MILLION)
  • TABLE 62 US: INTERVENTIONAL ONCOLOGY MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 63 US: INTERVENTIONAL ONCOLOGY ABLATION DEVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 64 US: INTERVENTIONAL ONCOLOGY EMBOLIZATION DEVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 65 US: INTERVENTIONAL ONCOLOGY SUPPORT DEVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 66 CANADA: INTERVENTIONAL ONCOLOGY MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 67 CANADA: INTERVENTIONAL ONCOLOGY ABLATION DEVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 68 CANADA: INTERVENTIONAL ONCOLOGY EMBOLIZATION DEVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 69 CANADA: INTERVENTIONAL ONCOLOGY SUPPORT DEVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 70 EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 71 EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 72 EUROPE: INTERVENTIONAL ONCOLOGY ABLATION DEVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 73 EUROPE: INTERVENTIONAL ONCOLOGY EMBOLIZATION DEVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 74 EUROPE: INTERVENTIONAL ONCOLOGY SUPPORT DEVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 75 EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2017-2024 (USD MILLION)
  • TABLE 76 EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2017-2024 (USD MILLION)
  • TABLE 77 GERMANY: INTERVENTIONAL ONCOLOGY MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 78 GERMANY: INTERVENTIONAL ONCOLOGY ABLATION DEVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 79 GERMANY: INTERVENTIONAL ONCOLOGY EMBOLIZATION DEVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 80 GERMANY: INTERVENTIONAL ONCOLOGY SUPPORT DEVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 81 UK: INTERVENTIONAL ONCOLOGY MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 82 UK: INTERVENTIONAL ONCOLOGY ABLATION DEVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 83 UK: INTERVENTIONAL ONCOLOGY EMBOLIZATION DEVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 84 UK: INTERVENTIONAL ONCOLOGY SUPPORT DEVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 85 FRANCE: INTERVENTIONAL ONCOLOGY MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 86 FRANCE: INTERVENTIONAL ONCOLOGY ABLATION DEVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 87 FRANCE: INTERVENTIONAL ONCOLOGY EMBOLIZATION DEVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 88 FRANCE: INTERVENTIONAL ONCOLOGY SUPPORT DEVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 89 ROE: INTERVENTIONAL ONCOLOGY MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 90 ROE: INTERVENTIONAL ONCOLOGY ABLATION DEVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 91 ROE: INTERVENTIONAL ONCOLOGY EMBOLIZATION DEVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 92 ROE: INTERVENTIONAL ONCOLOGY SUPPORT DEVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 93 ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 94 ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 95 ASIA PACIFIC: INTERVENTIONAL ONCOLOGY ABLATION DEVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 96 ASIA PACIFIC: INTERVENTIONAL ONCOLOGY EMBOLIZATION DEVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 97 ASIA PACIFIC: INTERVENTIONAL ONCOLOGY SUPPORT DEVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 98 ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2017-2024 (USD MILLION)
  • TABLE 99 ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2017-2024 (USD MILLION)
  • TABLE 100 JAPAN: INTERVENTIONAL ONCOLOGY MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 101 JAPAN: INTERVENTIONAL ONCOLOGY ABLATION DEVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 102 JAPAN: INTERVENTIONAL ONCOLOGY EMBOLIZATION DEVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 103 JAPAN: INTERVENTIONAL ONCOLOGY SUPPORT DEVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 104 CHINA: INTERVENTIONAL ONCOLOGY MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 105 CHINA: INTERVENTIONAL ONCOLOGY ABLATION DEVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 106 CHINA: INTERVENTIONAL ONCOLOGY EMBOLIZATION DEVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 107 CHINA: INTERVENTIONAL ONCOLOGY SUPPORT DEVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 108 INDIA: INTERVENTIONAL ONCOLOGY MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 109 INDIA: INTERVENTIONAL ONCOLOGY ABLATION DEVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 110 INDIA: INTERVENTIONAL ONCOLOGY EMBOLIZATION DEVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 111 INDIA: INTERVENTIONAL ONCOLOGY SUPPORT DEVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 112 ROAPAC: INTERVENTIONAL ONCOLOGY MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 113 ROAPAC: INTERVENTIONAL ONCOLOGY ABLATION DEVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 114 ROAPAC: INTERVENTIONAL ONCOLOGY EMBOLIZATION DEVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 115 ROAPAC: INTERVENTIONAL ONCOLOGY SUPPORT DEVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 116 LATAM: INTERVENTIONAL ONCOLOGY MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 117 LATAM: INTERVENTIONAL ONCOLOGY MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 118 LATAM: INTERVENTIONAL ONCOLOGY ABLATION DEVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 119 LATAM: INTERVENTIONAL ONCOLOGY EMBOLIZATION DEVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 120 LATAM: INTERVENTIONAL ONCOLOGY SUPPORT DEVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 121 LATAM: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2017-2024 (USD MILLION)
  • TABLE 122 LATAM: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2017-2024 (USD MILLION)
  • TABLE 123 BRAZIL: INTERVENTIONAL ONCOLOGY MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 124 BRAZIL: INTERVENTIONAL ONCOLOGY ABLATION DEVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 125 BRAZIL: INTERVENTIONAL ONCOLOGY EMBOLIZATION DEVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 126 BRAZIL: INTERVENTIONAL ONCOLOGY SUPPORT DEVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 127 MEXICO: INTERVENTIONAL ONCOLOGY MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 128 MEXICO: INTERVENTIONAL ONCOLOGY ABLATION DEVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 129 MEXICO: INTERVENTIONAL ONCOLOGY EMBOLIZATION DEVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 130 MEXICO: INTERVENTIONAL ONCOLOGY SUPPORT DEVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 131 ROLA: INTERVENTIONAL ONCOLOGY MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 132 ROLA: INTERVENTIONAL ONCOLOGY ABLATION DEVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 133 ROLA: INTERVENTIONAL ONCOLOGY EMBOLIZATION DEVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 134 ROLA: INTERVENTIONAL ONCOLOGY SUPPORT DEVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 135 MEA: INTERVENTIONAL ONCOLOGY MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 136 MEA: INTERVENTIONAL ONCOLOGY ABLATION DEVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 137 MEA: INTERVENTIONAL ONCOLOGY EMBOLIZATION DEVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 138 MEA: INTERVENTIONAL ONCOLOGY SUPPORT DEVICES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 139 MEA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2017-2024 (USD MILLION)
  • TABLE 140 MEA: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2017-2024 (USD MILLION)

LIST OF FIGURES

  • FIGURE 1 INTERVENTIONAL ONCOLOGY MARKET: RESEARCH METHODOLOGY STEPS
  • FIGURE 2 RESEARCH DESIGN
  • FIGURE 3 BREAKDOWN OF PRIMARIES: GLOBAL INTERVENTIONAL ONCOLOGY MARKET
  • FIGURE 4 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
  • FIGURE 5 BOTTOM-UP APPROACH MARKET SIZE ESTIMATION: INTERVENTIONAL ONCOLOGY MARKET
  • FIGURE 6 TOP-DOWN APPROACH MARKET SIZE ESTIMATION: INTERVENTIONAL ONCOLOGY MARKET
  • FIGURE 7 DATA TRIANGULATION METHODOLOGY
  • FIGURE 8 INTERVENTIONAL ONCOLOGY MARKET SHARE, BY PRODUCT, 2018
  • FIGURE 9 INTERVENTIONAL ONCOLOGY MARKET SHARE, BY PROCEDURE, 2018
  • FIGURE 10 INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019 VS. 2024 (USD MILLION)
  • FIGURE 11 GEOGRAPHICAL SNAPSHOT OF THE INTERVENTIONAL ONCOLOGY MARKET
  • FIGURE 12 RISING PREFERENCE FOR MINIMALLY INVASIVE PROCEDURES IS DRIVING THE GROWTH OF THE INTERVENTIONAL ONCOLOGY MARKET
  • FIGURE 13 ASIA PACIFIC REGIONAL SEGMENT TO WITNESS HIGH GROWTH IN THE PRODUCTS MARKET DURING THE FORECAST PERIOD
  • FIGURE 14 RADIOFREQUENCY ABLATION SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE ASIA PACIFIC ABLATION DEVICES MARKET IN 2018
  • FIGURE 15 LIVER CANCER SEGMENT COMMANDED THE LARGEST SHARE OF THE EUROPEAN INTERVENTIONAL ONCOLOGY MARKET IN 2018
  • FIGURE 16 THERMAL TUMOR ABLATION SEGMENT TO WITNESS THE HIGHEST GROWTH IN THE FORECAST PERIOD
  • FIGURE 17 ASIA PACIFIC TO REGISTER THE HIGHEST CAGR IN THE INTERVENTIONAL ONCOLOGY MARKET DURING THE FORECAST PERIOD
  • FIGURE 18 INTERVENTIONAL ONCOLOGY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 19 LIVER CANCER SEGMENT TO DOMINATE THE INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, DURING THE FORECAST PERIOD
  • FIGURE 20 INTERVENTIONAL ONCOLOGY MARKET: GEOGRAPHIC SNAPSHOT
  • FIGURE 21 NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET SNAPSHOT
  • FIGURE 22 ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET SNAPSHOT
  • FIGURE 23 KEY DEVELOPMENTS IN THE INTERVENTIONAL ONCOLOGY MARKET FROM 2015 TO 2019
  • FIGURE 24 MEDTRONIC HELD THE LEADING POSITION IN THE INTERVENTIONAL ONCOLOGY MARKET IN 2017
  • FIGURE 25 VENDOR DIVE: EVALUATION OVERVIEW
  • FIGURE 26 TELEFLEX: COMPANY SNAPSHOT
  • FIGURE 27 TERUMO CORPORATION: COMPANY SNAPSHOT
  • FIGURE 28 MEDTRONIC: COMPANY SNAPSHOT
  • FIGURE 29 BTG PLC: COMPANY SNAPSHOT 158  
  • FIGURE 30 JOHNSON & JOHNSON: COMPANY SNAPSHOT
  • FIGURE 31 MERIT MEDICAL: COMPANY SNAPSHOT
  • FIGURE 32 BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT
  • FIGURE 33 ANGIODYNAMICS: COMPANY SNAPSHOT
Back to Top